Galmed Pharmaceuticals
GLMD
21 hedge funds and large institutions have $5.99M invested in Galmed Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
5% less funds holding
Funds holding: 22 → 21 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
28% less capital invested
Capital invested by funds: $8.36M → $5.99M (-$2.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$54.3K |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$44.4K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$29.6K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$28K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAD
Craig A. Drill
|
-$160K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$118K |
| 3 |
Renaissance Technologies
New York
|
-$109K |
| 4 |
Goldman Sachs
New York
|
-$70.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$20K |
GLMD Hedge Fund Activity: Q3 2015 in Review
21 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2015, worth a combined $5.99M — down 28% from $8.36M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 7 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $54.3K. The largest seller was Craig A. Drill, exiting entirely with an estimated $160K sold.
- 21 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2015, down from 22 in Q2 2015.
- Funds reported $5.99M of Galmed Pharmaceuticals stock for Q3 2015, down 28% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q3 2015 and 4 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2015 was DAFNA Capital Management, an estimated $54.3K added.
- The largest Galmed Pharmaceuticals seller in Q3 2015 was Craig A. Drill, an estimated $160K sold.
Based on aggregated 13F filings for Q3 2015.